Zobrazeno 1 - 10
of 124
pro vyhledávání: ''
Autor:
Shigeyuki Shichino, Hiromichi Nakajima, Yoshiaki Nakamura, Tetsuya Nakatsura, Satoshi Ueha, Manami Shimomura, Hiroyasu Aoki, Akihiro Sato, Kouji Matsushima, Takayuki Yoshino
Publikováno v:
Cancer Science
With the widespread use of programmed death receptor‐1 (PD‐1) blockade therapy, sensitive and specific predictive biomarkers that guide patient selection are urgently needed. T‐cell receptor (TCR) repertoire, which reflects antitumor T‐cell r
Autor:
Kazuho Morichika, Shugo Sakihama, Hiroaki Masuzaki, Sawako Nakachi, Jun-Nosuke Uchihara, Kennosuke Karube, Shingo Nakayama, Kazuko Sakai, Satoko Morishima, Kazuto Nishio, Masaki Hayashi, Rumiko Saito, Takeaki Tomoyose, Takuya Fukushima, Megumi Miyara, Takashi Miyagi, Kazuiku Ohshiro
Publikováno v:
Cancer Science
Genetic alterations in adult T‐cell leukemia/lymphoma (ATLL), a T‐cell malignancy associated with HTLV‐1, and their clinical impacts, especially from the perspective of viral strains, are not fully elucidated. We employed targeted next‐genera
Autor:
Kosei Matsue, Chikashi Yoshida, Kaichi Nishiwaki, Naoki Takezako, Hisashi Sakamaki, Tadashi Murase, Takashi Kumagai, Satoshi Morita, Kazuteru Ohashi, Yasuji Kouzai, Shimousa Hematology Study Groups, Hisashi Wakita, Koiti Inokuchi, Hina Takano, Chiaki Nakaseko, Junichi Sakamoto
Publikováno v:
Cancer Science
Tyrosine kinase inhibitors (TKIs) improve the prognosis of patients with chronic myelogenous leukemia (CML) by inducing substantial deep molecular responses (DMRs); some patients could successfully discontinue TKI therapy after maintaining DMR for
Autor:
Naokuni Uike, Kazuhiro Kawai, Kensei Tobinai, Yoshitaka Imaizumi, Atae Utsunomiya, Masahiro Amano, Koichi Ohshima, Masako Iwanaga, Yoji Ishida, Kunihiro Tsukasaki, Kenji Ishitsuka, Takashi Ishida, Junji Tanaka, Kaoru Uchimaru, Toshiki Watanabe, Kenichi Ishizawa, Yoshiki Tokura, Kisato Nosaka
Publikováno v:
Cancer Science
Adult T-cell leukemia-lymphoma (ATL) is a mature T-cell malignancy associated with human T-cell leukemia virus type 1 (HTLV-1) infection. Japan is the most endemic country for HTLV-1 and ATL in the world. Recent nationwide studies of Japanese blood d
Autor:
Yoshihiko Hirohashi, Emi Mizushima, Munehide Nakatsugawa, Noriyuki Sato, Makoto Emori, Toshihiko Torigoe, Takayuki Kanaseki, Tomohide Tsukahara, Yuji Shibayama, Toshihiko Yamashita, Kenji Murata, Terufumi Kubo
Publikováno v:
Cancer Science
Chemotherapy has improved the prognosis of patients with sarcomas. However, it may suppress anti-tumor immunity. Recently, we reported a novel CD8+ memory T cell population with a chemo-resistance property, “young memory” T (TYM) cells. In this s
Autor:
Mizuno, Ryuichi, Kimura, Go, Fukasawa, Satoshi, Ueda, Takeshi, Kondo, Tsunenori, Hara, Hidehiko, Shoji, Sunao, Kanao, Kent, Nakazawa, Hayakazu, Tanabe, Kazunari, Horie, Shigeo, Oya, Mototsugu, Yuasa, T., Horiguchi, A., Nakaigawa, N., Oyama, M., Nagata, H., Ishida, M., Kawata, N., Hatano, T., Kishida, T., Morita, J., Yamaguchi, R., Nakagawa, T., Kume, H.
Publikováno v:
Cancer Science
The objective of this prospective study was to identify baseline angiogenic and inflammatory markers in serum as well as the baseline levels of immune cells in whole blood to predict progression-free survival in patients with metastatic renal cell ca
Autor:
Hiromitsu Mimata, Wataru Obara, Fuminori Sato, Tamotsu Sugai, Yusuke Nakamura, Ryo Takata, Tomoaki Fujioka, Renpei Kato, Yoichiro Kato, Mitsugu Kanehira, Kazuyoshi Takeda
Publikováno v:
Cancer Science
We screened cell division associated 1 (CDCA1) as an oncogene that is overexpressed on several cancers, including prostate cancer. We also identified a highly immunogenic HLA-A*2402-restricted epitope peptide corresponding to part of the CDCA1 protei
Autor:
Naoya Yamazaki, Manabu Fujimoto, Hisashi Uhara, Hiroshi Uchi, Hironobu Ihn, Yoshio Kiyohara, Hironobu Minami, Masaki Otsuka, Tatsuya Takenouchi, Jiro Uehara
Publikováno v:
Cancer Science
Treating advanced or recurrent melanoma remains a challenge. Cancer cells can evade the immune system by blocking T-cell activation through overexpression of the inhibitory receptor programmed death 1 (PD-1) ligands. The PD-1 inhibitor nivolumab bloc
Autor:
Tatsuya Takenouchi, Jiro Uehara, Hironobu Ihn, Taiki Isei, Naoya Yamazaki, Hiroshi Uchi, Hisashi Uhara, Hideaki Tahara, Yoshio Kiyohara, Hironobu Minami, Fujio Otsuka, Yasuhiro Fujisawa, Keiji Iwatsuki, Hajime Iizuka
Publikováno v:
Cancer Science
Promising antitumor activities of nivolumab, a fully humanized IgG4 inhibitor antibody against the programmed death-1 protein, were suggested in previous phase 1 studies. The present phase 2, single-arm study (JAPIC-CTI #111681) evaluated the antitum
Autor:
Mai Noujima-Harada, Etsuro Ito, Katsuyoshi Takata, Tomoko Miyata-Takata, Kazuhiko Igarashi, Shizuma Omote, Hiroaki Sakurai, Kohei Taniguchi, Tetsuya Tabata, Nobuhiko Ohnishi, Tadashi Yoshino, Yasuharu Sato, Keina Nagakita
Publikováno v:
Cancer Science
Diffuse large B‐cell lymphoma (DLBCL) is the most common B‐cell lymphoma subtype, and the Epstein–Barr virus (EBV)‐positive subtype of DLBCL is known to show a more aggressive clinical behavior than the EBV‐negative one. BTB and CNC homolog